What did we get?, page-8

DS sold 20 million yens worth of Inavir.

If ever a good compound was screwed up by a pharmaceutical company, this was it. First, letting tamiflu beat relenza in the US, then letting inavir die in fully funded but poorly designed and poorly executed US trials. Why? Because they sold the company cheap and brought in poor managers.

DS saw the potential in the compound so early. Biota were just stupid.